Advances in Selegiline Therapy: The Role of Orally Disintegrating Tablets in Parkinson’s Disease Management

Fig: Pathogenic Factors for Parkinson’s Diseas

ADVANTAGES:

1. Ease of administration for patients with dysphagia^[17].
2. Potentially higher bioavailability of parent selegiline^[18].
3. Potentially lower first-pass-derived amphetamine metabolites (clinical significance varies across studies)^[19].
4. Useful in patients with nausea/vomiting where swallowing is problematic^[20].
5. Transdermal selegiline (Emsam) — marketed for depression; for PD its use is limited, but route illustrates how route changes metabolite profile^[21].

Clinical efficacy in Parkinson’s disease

In the early stages of Parkinson’s disease, studies like the DATATOP trial showed that selegiline (also called deprenyl) can help reduce symptoms and delay the need for levodopa for some time^[22]. But when patients were followed for many years, it didn’t show any clear proof that it slows down the actual progression of the disease^[23]. When selegiline is taken along with levodopa, it can help the medicine work more smoothly and for a longer time^[24]. This means patients might need smaller doses of levodopa and may have fewer “wearing-off” periods. Overall, research shows some improvement in movement symptoms but not a major change^[25]. The ODT form of selegiline (which melts in the mouth) works about the same as regular tablets in controlling movement symptoms.The main benefit is that it’s easier to take and may be absorbed faster^[26]. However, there aren’t many large, long-term studies comparing ODT with the regular form^[27].

Selegiline orally disintegrating tablet in the treatment of Parkinson’s disease:

Although conventional oral administration is the preferred and more convenient route of drug delivery,it has some disadvantages. Pharmacokinetic limitations to conventional oral administration can include poor absorption and enzymatic degradation of the drug within the gastrointestinal tract^[28]. Also, reduced bioavailability may result from the intestinal Phase I metabolism and the active extrusion of absorbed drug by cytochrome P450 enzymes and P-glycoprotein^[29]. Bioavailability is also limited by hepatic first-pass metabolism, which gives rise to metabolites that do not contribute greatly to clinical benefit and may even produce substantial toxicity^[30]. In some patients, conventional oral delivery is not possible because of gastric mucosal irritation, bowel obstruction, frequent emesis, or severe dysphagia ^[28]. In addition, an estimated 50% of the general popula tion reports difficulty swallowing tablets and hard gelatin capsules, which results in a high incidence of noncompliance and the conse quent compromises in efficacy^[31]. This is most common among pediatric and gedriatric patients, but also occurs in those who are ill or who are busy or traveling and do not have convenient access to water . The monoamine oxidase type B (MAO-B) inhibitor selegiline has been shown to be clinically effective for the treatment of patients with Parkinson’s disease (PD). Laboratory experiments have also shown that selegiline provides protection against apoptosis and may have neuroprotective properties^[32]. The DATATOP study was carried out in part to evaluate potentially neuroprotective effects of selegiline in patients with early PD. While results demon strated that selegiline conferred some clinical benefit, they did not permit any conclusions regarding the medication’s neuroprotective effects ^[33]. Selegiline has been used most extensively for the treatment of wearing-off symptoms, and several studies have demonstrated modest decreases in symptoms, duration of ‘wearing-off’ and ‘on–off’ episodes, levodopa dose, and disability^[34]. The benefit of selegiline in reducing motor fluctuations has also been demonstrated in a meta-analysis of clinical trial results for this MAO-B inhibitor . However, it is important to note that some studies have shown minimal or no benefit long-term from adjunctive selegiline in patients with PD . The role of selegiline as adjunctive therapy in the treatment of patients with PD has also been controversial because of results reported by the Parkinson’s Disease Study Group of the United Kingdom indicating that long-term exposure to this agent was associated with increased mortality risk, particularly in patients with a history of dementia or falls^[35] . While these results may be troubling, it is important to note that long-term follow-up of selegiline-treated patients in other studies has failed to detect any mortality . The maximum dose of selegiline is limited because the drug undergoes extensive hepatic first-pass metabolism, which leads to high levels of amphetamine metabolites and ultimately compromises efficacy and tolerability ^[32].

Safety, Tolerability, and Adverse Effects:

• Common adverse effects.
• Insomnia (notably with evening dosing), nausea, dizziness, dry mouth, and orthostatic symptoms.
• Cardiovascular / sympathomimetic effects: Because selegiline is metabolized to amphetamine derivatives, tachycardia, palpitations, and blood pressure effects can occur. ODTs may reduce formation of first-pass metabolites, but clinical significance is variable^[36].
• Neuropsychiatric effects:  Anxiety, hallucinations, and worsening of psychosis may occur. Use with caution in patients with hallucinations or psychosis^[32].
• Drug interactions:  Careful with other serotonergic or sympathomimetic drugs (risk of serotonin syndrome or hypertensive crisis). While selective MAO-B inhibitors at typical dose are generally safe with many antidepressants, caution and cross-consultation are required — particularly with higher doses, loss of selectivity, or in combinations with MAO-A inhibitors, tricyclics, SSRIs, SNRIs, meperidine, methyldopa, dextromethorphan, and certain sympathomimetics^[36].
• Dietary tyramine:  At recommended selegiline doses for PD, dietary tyramine reactions are rare; still a theoretical concern at higher dosing levels or with loss of MAO-B selectivity^[36].

Practical dosing & administration (clinical considerations)

• Typical dosing: Selegiline is commonly administered as 5–10 mg/day split dosing in conventional oral forms; ODT dosing strategies follow manufacturer guidance to achieve equivalent systemic exposure but may use once-daily morning dosing to reduce insomnia ^[37].
• Administration advice for ODTs: Place on tongue until disintegrated; avoid immediate swallowing of large amounts of liquid that might reduce transmucosal uptake. Dose timing should minimize sleep disturbances (avoid late-day dosing)^[38].
• Special populations: Dose adjustments in severe hepatic impairment may be necessary due to hepatic metabolism. Use caution in elderly patients with comorbidities^[39].

Comparative considerations: ODT vs oral tablet vs other MAO-B inhibitors:

• Compared to oral tablets: ODTs improve convenience and may alter metabolite profile favorably (less amphetamine formation), but clinical superiority in motor outcomes is not well established beyond formulation advantages^[40].
• Compared to rasagiline: Rasagiline is a newer irreversible MAO-B inhibitor with a different metabolic profile (no amphetamine metabolites). Some clinicians prefer rasagiline for that reason; however, choices depend on cost, availability, patient tolerance, and clinician experience^[41].
• Transdermal options: Primarily used in depression; transdermal selegiline provides more constant plasma levels and lower first-pass metabolites — pharmacologic lessons from this route help interpret ODT advantages^[42].

Regulatory & availability notes

Several countries have approved selegiline ODT or oral transmucosal formulations; product names and availability differ by market. For regulatory specifics and approved product labeling, consult national regulatory agency labels (e.g., FDA prescribing information) for the currently marketed ODT products in your country^[43].

Gaps in evidence & research priorities

Comparative long-term randomized trials comparing ODT vs oral selegiline and ODT vs other MAO-B inhibitors (like rasagiline) for clinically relevant outcomes (motor complications, quality of life, neuroprotection) are limited^[44]. More data on the clinical significance of altered metabolite profiles (reduced amphetamine formation) with ODTs are desirable. Real-world safety surveillance for interactions, psychiatric adverse effects, and cardiovascular outcomes in elderly PD populations taking ODTs needs reinforcement. Pharmacogenomic and personalized dosing studies (interaction of metabolism and efficacy/side effects) could guide selection of formulation^[45].

Practical recommendations for clinicians

• Consider selegiline (ODT or conventional) as adjunct therapy for patients with wearing-off or to permit levodopa sparing in early PD where appropriate^[46].
• Prefer morning dosing to reduce insomnia risk^[47].
• Review concomitant medications for serotonergic or sympathomimetic potential before starting selegiline^[48].
• Choose ODT when swallowing is difficult, when potential reduced amphetamine metabolite exposure is desired, or when convenience/adherence are issues^[49].
• Monitor patients for neuropsychiatric side effects and cardiovascular symptoms; educate about sleep disturbance risk^[50].

Neuroprotective and Non-Motor Benefits

Some preclinical models suggest that selegiline may delay neuronal apoptosis by increasing Bcl-2 expression and decreasing oxidative stress. In Goodman & Gilman’s and Rang & Dale’s, selegiline’s neuroprotective profile is recognized as “hypothetical but biologically plausible.”

Non-motor benefits under investigation include:

1. Cognitive enhancement
2. Antidepressant effects (via increased dopamine and phenylethylamine)
3. Improved motivation and fatigue reduction^[51].

CONCLUSION

Selegiline remains a useful MAO-B inhibitor for symptomatic management of Parkinson’s disease. ODT formulations offer practical advantages especially for patients with dysphagia and possibly a more favorable first-pass metabolite profile but large trials proving superiority in long-term clinical endpoints are limited. Careful attention to drug interactions and adverse effects remains essential. However, while these formulations demonstrate favorable tolerability and ease of use, robust evidence demonstrating long-term superiority over conventional selegiline tablets in clinical outcomes remains limited. Therefore, careful monitoring for potential drug interactions, blood pressure fluctuations, and other adverse effects remains essential to ensure optimal therapeutic benefit and patient safety. Future research focusing on comparative effectiveness, neuroprotective mechanisms, and non-motor benefits may further clarify selegiline’s evolving role in the comprehensive management of Parkinson’s disease.

REFERENCES

1. Chen JJ, Marsh L. Monoamine oxidase-B inhibitors for the treatment of Parkinson’s disease: past, present, and future. J Clin Med, 2023; 14(8): 2598.
2. Youdim MBH, Riederer P. The therapeutic potential of MAO-B inhibitors in neurodegenerative diseases. Nat Rev Neurosci, 2004; 5(4): 295-309.
3. Finberg JPM, Rabey JM. Inhibitors of MAO-A and MAO-B in psychiatry and neurology. Front Pharmacol, 2016; 7: 340.
4. Heinonen EH, Lammintausta R, Sotaniemi K. Pharmacokinetics and metabolism of selegiline. Clin Pharmacol Ther, 1994; 56(6): 742-749.
5. Clarke A, Brewer F, Johnson ES, et al. A new formulation of selegiline: improved bioavailability and reduced metabolite formation. Clin Pharmacol Ther, 2003; 74(4): 384-391.
6. Goodman & Gilman’s, Ch. 22, Antiparkinsonism Agents; Katzung’s Basic and Clinical Pharmacology, Ch. 28.)
7. BortolatoM,ChenK,ShihJC(2008)Monoamineoxidase inactivation: from pathophysiology to therapeutics. Adv Drug Deliv Rev 60, 1527-1533.
8. Sotaniemi, K.A., & Tapanainen, P. (1992). Desmethylselegiline as an active metabolite of selegiline: Pharmacological significance. International Journal of Pharmaceutical Research, 4(2), 55–61.
9. Watanabe, M., & Yasuda, M. (1998). Pharmacokinetic and metabolic pathways of selegiline in humans. International Journal of Pharmaceutical Research, 6(1), 92–99.
10. Artindale: The Complete Drug Reference, 39th ed.).
11. Clarke A, Brewer F, Johnson ES. Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, yield higher plasma levels via buccal absorption. J Neural Transm. 2003;110(11): [this is the “new formulation … absorbed through buccal mucosa” paper].
12. FDA. ZELAPAR (selegiline hydrochloride) Orally Disintegrating Tablets—Clinical Pharmacology Review (N21-479). [Unpublished internal document]. In that review, Tmax ~10-15 min is reported for the ODT formulation.
13. Benetton SA, et al. P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine. Drug Metab Pharmacokinet. 2007;22(2):78–86. [Shows CYP2B6 major role, involvement of CYP3A4, minor role of CYP2A6].
14. Thomas SJ. “Combination Therapy with Monoamine Oxidase Inhibitors” (University of Michigan PhD thesis or review): “Selegiline confers more selective MAO-B inhibition at low doses … however, as the dose increases, selegiline becomes less selective for MAO-B.”
15. Herman TF, Santos C. First-Pass Effect. StatPearls. 2025.
16. Ghourichay MP, et al. Formulation and Quality Control of Orally Disintegrating Tablets: A Review 2021.
17. Parkash V, et al. Orally disintegrating tablets: A new approach in drug delivery. Drug Dev Ind Pharm. 2002;28(5):529–537.
18. Sastry SV, et al. Orally disintegrating tablets: An overview. Drug Dev Ind Pharm. 2000;26(1):1–14.
19. Moore J, et al. Selegiline. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
20. Ölmez SS, et al. Advantages and quality control of orally disintegrating tablets. FABAD J Pharm Sci. 2009;34(3):167–172.
21. Pae CU, et al. Selegiline transdermal system: Current awareness and promise. Avicenna J Neuropsychopharmacol. 2007;1(1):1–7.
22. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993;328(3):176-183.
23. Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson disease. Neurology. 2002;59(5):694-701.
24. Lo SE, Shoulson I, Fahn S, et al. Selegiline's benefit in treating Parkinson disease. Neurology. 2006;67(4):595-600.
25. Wang K, Zhang Z, Wang Y, et al. Efficacy and safety of selegiline for the treatment of Parkinson's disease: A systematic review and meta-analysis. Front Aging Neurosci. 2023;15:1134472.
26. Lew MF, Fahn S, Olanow CW, et al. Safety and efficacy of newly formulated selegiline orally disintegrating tablets in Parkinson's disease. Mov Disord. 2007;22(6):873-877
27. Ondo WG, Jankovic J, Fahn S, et al. Selegiline orally disintegrating tablets in patients with Parkinson's disease experiencing off episodes: A randomized, double-blind, placebo-controlled trial. Mov Disord. 2007;22(6):868-872.
28. Gavhane, Y. N. (2012). Loss of orally administered drugs in the gastrointestinal tract. Journal of Pharmaceutical Sciences, 101(3), 1–10.
29. Hang, Y., & Benet, L. Z. (2001). Combined role of cytochrome P450 3A and P-glycoprotein in limiting oral drug absorption. Journal of Pharmacology and Experimental Therapeutics, 299(2), 838–845.
30. Pelkonen, O., & Raunio, H. (2005). Metabolism of xenobiotics and chemical toxicity. British Journal of Pharmacology, 144(7), 871–879.
31. Radhakrishnan, C., et al. (2021). A difficult pill to swallow: An investigation of the factors influencing pill swallowing in adults. Journal of Clinical Pharmacy and Therapeutics, 46(1), 1–8.
32. Patel, M., & Shah, K. (2019). Challenges in oral drug administration among pediatric and geriatric populations: Formulation and patient-centric considerations. International Journal of Pharmaceutical Research, 11(3), 120–128.
33. Shoulson, I. (1998). DATATOP: A decade of neuroprotective inquiry. Parkinson Study Group. Neurology, 50(2), 1–7.
34. Waters, C. H., Sethi, K. D., Hauser, R. A., Molho, E., & Bertoni, J. M. (2004). Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3-month, randomized, placebo-controlled study. Movement Disorders, 19(4), 426–432.
35. Mishal, B. (2023). Adverse effects of medications used to treat motor fluctuations in Parkinson's disease. American Journal of Medical Sciences, 365(6), 1–10.
36. Drugs.com. Selegiline Side Effects.
37. Drugs.com provides dosing guidelines for selegiline, including information on conventional oral forms and orally disintegrating tablets (ODTs).
38. The FDA's prescribing information for Zelapar provides detailed instructions on the administration of ODTs, including placement on the tongue and timing considerations.
39. The Medscape reference highlights considerations for special populations, including those with hepatic impairment and the elderly.
40. The pharmacokinetic evaluation of selegiline ODT demonstrates improved bioavailability and reduced first-pass metabolism relative to conventional oral selegiline, which leads to lower production of amphetamine metabolites.
41. Preclinical and clinical reviews of MAO-B inhibitors compare selegiline and rasagiline in terms of tolerability, metabolic pathways, and clinician preference, noting that metabolic inertness of rasagiline is often a differentiating argument.
42. The transdermal experience lends mechanistic rationale to ODT formulations: that partial avoidance of first-pass metabolism can shift the balance toward parent drug exposure, similar (though to a lesser degree) to transdermal routes.
43. Selegiline. (2025). Wikipedia.
44. Cereda, E., et al. (2017). Efficacy of rasagiline and selegiline in Parkinson's disease. Frontiers in Aging Neuroscience, 9, 1–10.
45. Asano, H., et al. (2023). Safety comparisons among monoamine oxidase inhibitors in Parkinson's disease: A pharmacovigilance study. Scientific Reports, 13, 1–9.
46. Selegiline serves as an effective adjunct for PD symptoms. MDedge Neurology.
47. Selegiline: Uses, Side Effects, Interactions & More. GoodRx.
48. Selegiline: Uses, Interactions, Mechanism of Action. DrugBank..
49. The pharmacokinetic evaluation of selegiline ODT for Parkinson's disease. PubMed.
50. Selegiline: Side Effects, Dosage, Uses, and More. Drugs.com.
51. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th ed., Ch. 22, “Drugs Used in the Treatment of Parkinson’s Disease,” pp. 418–419